---
title: "Keros Therapeutics names Annita Tanini interim CFO as Keith Regnante resigns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293513881.md"
description: "Keros Therapeutics announced that CFO Keith Regnante resigned effective August 3, 2026. Corporate Controller Annita Tanini was appointed interim principal financial officer and principal accounting officer starting August 4, 2026. Tanini has held finance leadership roles at the company since May 2019. The firm is currently conducting a search for a permanent replacement for the CFO position."
datetime: "2026-07-22T20:02:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293513881.md)
  - [en](https://longbridge.com/en/news/293513881.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293513881.md)
generator: "portal-rs"
---

# Keros Therapeutics names Annita Tanini interim CFO as Keith Regnante resigns

-   Keros Therapeutics CFO Keith Regnante resigned, effective Aug. 3, 2026, to pursue other opportunities. \* Corporate Controller Annita Tanini was named interim principal financial officer and principal accounting officer, effective Aug. 4, 2026. \* Tanini has held finance leadership roles at Keros since May 2019, most recently as corporate controller and vice president, finance. \* Her prior roles include vice president of finance at Avedro and senior vice president of finance at Fiksu. \* A search is underway for a new CFO. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-26-000038), on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [KROS.US](https://longbridge.com/en/quote/KROS.US.md)

## Related News & Research

- [Keros Therapeutics director Charles W. Newton sells 551 common shares worth $5,675.3](https://longbridge.com/en/news/296531453.md)
- [Keros Therapeutics director Jean Jacques Bieneaime acquires USD 10,270 in common shares](https://longbridge.com/en/news/296395349.md)
- [Annita Tanini Sells 1,224 Shares of Keros Therapeutics (NASDAQ:KROS) Stock](https://longbridge.com/en/news/296537997.md)
- [Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock](https://longbridge.com/en/news/296537934.md)
- [Plazza posts H1 2026 interim report online](https://longbridge.com/en/news/296736136.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**